sabcs 2022: destiny-breast02 destiny-breast03
Published 1 year ago • 243 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
1:08
destiny-breast02: t-dxd in her2 metastatic breast cancer previously treated with t-dm1
-
1:20
updated results of destiny-breast03: t-dxd vs t-dm1 in metastatic her2 breast cancer
-
4:25
destiny-breast03: safety follow-up results
-
3:06
updated findings of t-dxd in destiny-breast02 at esmo breast 2024
-
1:21
metastatic breast cancer: enhertu stops the spread
-
5:11
destiny-breast04: t-dxd provides significant improvement in os pfs in her2-low mbc
-
5:45
#esmo21 expert video report on targeting in her2-positive metastatic breast and lung cancers
-
4:08
sabcs 2022 highlights
-
12:19
sabcs 2022: updated survival results of the randomized, phase 3 study destiny-breast03 q & a
-
1:06
sabcs 2022 highlights
-
3:09
destiny-breast02: high levels of efficacy of t-dxd in previously treated her2 breast cancer
-
0:48
highlights from esmo: destiny-breast03
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
0:51
sabcs 2022: key highlights
-
11:35
sabcs 2022: primary results of the randomized, phase 3 study destiny-breast02 q & a
-
2:48
destiny-breast03: t-dxd is superior to t-dm1 in her2 metastatic breast cancer
-
2:00
sabcs 2022 takeaways
-
1:03
key takeaways from sabcs 2022
-
0:55
key highlights from sabcs 2022
-
1:12
trastuzumab deruxtecan in metastatic her2 breast cancer
-
1:16
key data at sabcs 2022